ALNY ▼ -4.9% - Alnylam Pharmaceuticals, Inc. $ALNY -5% this morning Sellside comments re: the 1.14 event rate ratio from the stabilizer (combo) arm of the CARDIO-TTRansform study -- ADAM F STAT NEWS Alnylam shares fell 4.9% following negative analyst commentary on interim data from the CARDIO-TTRansform study, specifically citing a 1.14 event rate ratio from the stabilizer combination arm. The result appears to have disappointed expectations for the company's cardiovascular TTR amyloidosis program, prompting sellside analysts to reassess the candidate's clinical profile. 28-AUG-2026 07:58 AM ET